Biomarkers for assessing occupational exposures to 1,3-butadiene

被引:61
|
作者
Albertini, RJ
Sram, RJ
Vacek, PM
Lynch, J
Wright, M
Nicklas, JA
Boogaard, PJ
Henderson, RF
Swenberg, JA
Tates, AD
Ward, JB
机构
[1] Univ Vermont, Genet Toxicol Lab, Burlington, VT 05401 USA
[2] Lab Genet Ecotoxicol, Prague, Czech Republic
[3] Shell Internat Chem BV, Amsterdam, Netherlands
[4] Lovelace Resp Res Inst, Albuquerque, NM USA
[5] Univ N Carolina, Chapel Hill, NC USA
[6] Leiden Univ, Leiden, Netherlands
[7] Univ Texas, Med Branch, Galveston, TX 77550 USA
[8] Hlth & Safety Lab, Sheffield, S Yorkshire, England
关键词
D O I
10.1016/S0009-2797(01)00181-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The overall objective of this study was to evaluate a continuum of biomarkers in blood and urine for their sensitivities as indicators of low level occupational exposures to 1,3 butadiene (BD). The study design was largely cross-sectional, with biological samples collected within a short timeframe. Personal 8-h BD exposure measures were made on several occasions over a 60-day period for each potentially exposed worker in order provide maximum accuracy for this independent variable and to accommodate the different expression intervals of the several biomarkers. Co-exposures to styrene, toluene and benzene were also measured. The study included 24 BD monomer production workers (mean BD exposure =0.642 mg/m(3)), 34 polymerization workers (mean BD exposure =1.794 mg/ml) and 25 controls (mean BD exposure =0.023 mg/m(3)). The several biomarkers were measured by a consortium of investigators at different locations in the US and Europe. These biomarkers included: (1) metabolic genotypes (CYP2E1. EH, GST M1, GST T1, ADH2, ADH3), determined in Prague and Burlington. VT; (2) urinary M1 and M2 metabolites (1,2-dihydroxy-4-[N-acetylcysteinyl]-butane and 1-hydroxy-2-[N-acetyleysteinyl]-3-butene, respectively), determined in Albuquerque, NM and Leiden; (3) hemoglobin adducts (N-[2-dihydroxy-3-butenyl]valine = HBVal and N-[2,3,4-trihydroxybutyl]valine = THBVal), determined in Amsterdam and Chapel Hill, NC, respectively; (4) HPRT mutations determined by autoradiographic assay in Galveston, TX, with slides re-read in Burlington, VT; (6) hypoxanthine-guanine phosphoribosyltransferase (HPRT) mutations determined by cloning assay in Leiden with mutational spectra characterized in Burlington, VT; (7) sister chromatid exchanges and chromosome aberrations determined by standard methods and FISH analysis in Prague. Urinary M1 and M2 metabolites and HBVal and THBVal hemoglobin adducts were all significantly correlated with BD exposure levels, with adducts being the most highly associated. No significant relationships were observed between BD exposures and HPRT mutations or any of the cytogenetic endpoints, regardless of method of assay. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:429 / 453
页数:25
相关论文
共 50 条
  • [21] 1,3-BUTADIENE EXPOSURE
    KAUFFMAN, TF
    CHEMICAL & ENGINEERING NEWS, 1985, 63 (18) : 4 - 4
  • [22] DIACETOXYLATION OF 1,3-BUTADIENE
    DEVEKKI, AV
    YAKUSHKIN, MI
    KINETICS AND CATALYSIS, 1987, 28 (05) : 951 - 956
  • [23] Influence of metabolic genotypes on biomarkers of exposure to 1,3-butadiene in humans
    Fustinoni, S
    Soleo, L
    Warholm, M
    Begemann, P
    Rannug, A
    Neumann, HG
    Swenberg, JA
    Vimercati, L
    Foà, V
    Colombi, A
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1082 - 1090
  • [24] DIENE SYNTHESIS WITH 1-TRIMETHOXYSILYL-1,3-BUTADIENE AND 1-SILATRANYL-1,3-BUTADIENE
    VORONKOV, MG
    ADAMOVICH, SN
    RAKHLIN, VI
    MIRSKOV, RG
    ZHURNAL OBSHCHEI KHIMII, 1984, 54 (02): : 475 - 477
  • [25] Biomarkers of exposure to 1,3-butadiene as a basis for cancer risk assessment
    van Sittert, NJ
    Megens, HJJJ
    Watson, WP
    Boogaard, PJ
    TOXICOLOGICAL SCIENCES, 2000, 56 (01) : 189 - 202
  • [26] FAR U-V SPECTRA OF HEXAFLUORO 1,3-BUTADIENE AND 1,3-BUTADIENE
    POTTIER, RH
    SEMELUK, GP
    STEVENS, RDS
    SPECTROSCOPY LETTERS, 1969, 2 (12) : 369 - &
  • [27] 1,3-DIPHOSPHA-1,3-BUTADIENE
    APPEL, R
    FOLLING, P
    SCHUHN, W
    KNOCH, F
    TETRAHEDRON LETTERS, 1986, 27 (15) : 1661 - 1664
  • [28] 1,3-Butadiene: III. Assessing carcinogenic modes of action
    Kirman, Christopher R.
    Albertini, Richard A.
    Gargas, Michael L.
    CRITICAL REVIEWS IN TOXICOLOGY, 2010, 40 : 74 - 92
  • [29] An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene ( vol 366 , pg 1 , 2022)
    Valdez-Flores, C.
    Erraguntla, N.
    Budinsky, R.
    Cagen, S.
    Kirman, C. R.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 385
  • [30] 1-CYANO-1,3-BUTADIENE .3. THE DIMER OF 1-CYANO-1,3-BUTADIENE
    SNYDER, HR
    POOS, GI
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1949, 71 (04) : 1395 - 1396